This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 20, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on
Thursday, February 27, 2014. An investor conference call will follow on the same day at
4:30 p.m. ET.
The conference call will be hosted by
Dan Myers, President and Chief Executive Officer, and
Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and
Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at
A replay of the conference call will be available beginning
February 27, 2014 at
7:30 p.m. ET and ending on
March 6, 2014 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 3470651. A replay of the webcast will be available on the corporate website for one week, through
March 6, 2014.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., headquartered in
Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from
London by its wholly-owned subsidiary, Alimera Sciences Limited.
Investor Contact:ICR, LLC
SOURCE Alimera Sciences, Inc.